Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3042  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  » Next article
  » Previous article 
  » Table of Contents
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (137 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Materials and Me...
 »  Results
 »  Discussion
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed9742    
    Printed221    
    Emailed4    
    PDF Downloaded1378    
    Comments [Add]    
    Cited by others 44    

Recommend this journal

 


 
ORIGINAL ARTICLE
Year : 2007  |  Volume : 55  |  Issue : 1  |  Page : 46-49

Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country


Department of Neurology, All India Institute of Medical Sciences, New Delhi - 110 029, India

Date of Acceptance01-Nov-2006

Correspondence Address:
M V Padma
Department of Neurology, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.30426

Rights and Permissions

 » Abstract 

Background: Given the constraints of resources, thrombolysis for acute ischemic stroke (AIS) is under evaluation in developing countries. Prothrombin time (PT), platelet count and activated partial thromboplastin time (aPTT) may not be feasible within the time window. Aim: To evaluate the safety and efficacy of thrombolysis in selected patients without the coagulation profile. Design: Open, nonrandomized, observational study. Materials and Methods: Fifty-four stroke patients were classified using TOAST criteria (large artery atherosclerotic = 13; cardioembolic = 12; small vessel occlusion = 22; other determined etiology =three; undetermined etiology = four). The mean time to reach emergency was 2.4h (1.15-3.4), the mean door to CT, 24 min (10-47) and the door to recombinant tissue plasminogen activator (r-tPA) injection, 26.8 min (25-67). The NIHSS scores ranged from 11 to 22 (mean = 15.5 ± 2.7). Patients with history of liver or renal disease or those on anticoagulants were excluded. The PT, aPTT and platelet count were not done. Recombinant tissue plasminogen activator was administered at a dosage of 0.9 mg/Kg. Results: Thirty-five patients (65%) significantly improved on NIHSS at 48h (³4 points) (mean change = 10; range= 4-17). At one month, 43 (79%) improved on Barthel Index (mean change = 45%). One each developed small frontal lobe hemorrhage and recurrent stroke; one died of aspiration; and eight showed no improvement. Conclusions: Hyperacute thrombolysis was found useful and safe in selected patients with AIS even without the coagulation studies.


Keywords: rtPA, stroke, thrombolysis


How to cite this article:
Padma M V, Singh M B, Bhatia R, Srivastava A, Tripathi M, Shukla G, Goyal V, Singh S, Prasad K, Behari M. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007;55:46-9

How to cite this URL:
Padma M V, Singh M B, Bhatia R, Srivastava A, Tripathi M, Shukla G, Goyal V, Singh S, Prasad K, Behari M. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India [serial online] 2007 [cited 2019 Dec 8];55:46-9. Available from: http://www.neurologyindia.com/text.asp?2007/55/1/46/30426


Acute ischemic stroke (AIS) is one area in neurological clinical practice that has probably seen the greatest strides as far as an understanding of pathogenesis is concerned. This has led to advancements made in the treatment options available for patients suffering from ischemic stroke. Plenty of the nihilism that surrounded strokes is gradually being lifted along with the ignorance related to the condition, from both the minds of patients and the treating doctors. Most therapeutic options for AIS have one common feature; they generally have to be administered within a very narrow and specific time window. This is extremely pertinent if the drug-related adverse events have to be minimized and the therapeutic benefits maximized.

The National Institute of Neurological Disorders and Stroke (NINDS) study on the intravenous use of recombinant tissue plasminogen activator (rtPA) within three hours of a an AIS has shown the benefit of this form of treatment.[1] In order to be effective the protocol for institution of rtPA therapy must be strictly followed. The evidence for this form of therapy is of Level I.[2] When all accumulated evidence for rtPA therapy is considered, the relative risk reduction provided by it is 44%, absolute risk reduction is 13% and the number needed to treat to save one person from death or disability is seven.[3]

Many countries now routinely thrombolyze all patients of AIS who present within the three-hour time window and do not have any contraindication. However, many stroke units, especially those in the developing nations, are hampered by constraints of resources and lack of awareness. Feasibility of thrombolysis is still being evaluated at these centers. The hyperacute thrombolysis for stroke was started in the year 1995-1996 in India and in March 2002 at the All India Institute of Medical Center, a tertiary referral center in India. We assessed the outcome of patients treated with intravenous rtPA, including the incidence of intracerebral hemorrhage and other adverse events. The overall purpose of this paper is to report the current clinical practice of intravenous thrombolytic therapy for acute stroke in a tertiary referral center from a developing country.


 » Materials and Methods Top


We present the detailed data of the 54 patients treated at AIIMS in whom an adequate follow-up of six months is available. All of these patients were studied prospectively.

The variables that were specifically recorded for each patient treated with rtPA: time of symptom onset, time of arrival in the emergency department, time of CT scan examination and the time of rtPA administration. An extensive neurological examination including the baseline NIH Stroke scale (NIHSS) was performed in all patients. Other parameters noted were the demographic profile, stroke risk factors, baseline CT scan findings and the blood pressure measurements [Table - 1].

Potential benefits and significant risks, specifically the fourfold greater risk of symptomatic intracerebral hemorrhage[4] after thrombolytic treatment were discussed with all patients and/or their families and informed consent obtained. The rtPA protocol was based on protocols published by the American Heart Association and the American Academy of Neurology.[5],[6] Inclusion and exclusion criteria are shown in [Table - 2]. All patients had pretreatment CT scans that were read by the attending neurologist together with the radiologist. Each of our patients received 0.9 mg/Kg of intravenous rtPA up to a maximum of 90 mg, based on the estimated or actual body weight. Ten per cent of this calculated dose was injected as a bolus and the remainder infused over an hour. Heparin and aspirin were withheld for the first 24h after rtPA administration in all our patients. Hypertension was treated using intravenous labetolol or intravenous enalapril. Occasionally, injection nitroglycerine or nitroprusside was required.

Results of follow-up CT scans or MRI scans were recorded in all patients thrombolysed. The use of aspirin, clopidogrel, heparin, acitrom and antihypertensives during the hospital stay was noted. The peak blood pressure during rtPA administration as well as during the first 24h after the infusion was recorded. Using the TOAST criteria, stroke subtype was determined by the following classification: 1). Large artery atherosclerosis, 2). Cardio-embolic, 3). Small-vessel occlusion, 4). Stroke of other determined etiology, 5). Stroke of undetermined etiology. We obtained telephone or clinic follow-up with the patient and caregiver in all 54 cases and assessed the Barthel Activities of Daily Living Index. For analysis, we defined a good outcome as an improved NIHSS of ≥ 4 and a Barthel Index of ≥ 75%. At AIIMS, due to constraints of time and resources we deviated from the recommended NINDS protocol in excluding patients with a history of liver or renal disease and in not obtaining results of platelet counts, prothrombin time and activated partial thromboplastin time in patients prior to thrombolysis.


 » Results Top


Fifty-four patients received IV rtPA for AIS between March 2002 and March 2006. The stroke team was notified of 1096 patients suspected of having an acute stroke during this period. The most common reasons for disqualification from thrombolytic therapy were, exceeding the window period (38%), intracerebral hemorrhage (20%), minor or rapidly resolving symptoms (20%) and a nonstroke diagnosis (12%). Of the patients who could qualify to receive thrombolysis, 26% could not be thrombolyzed since they could not afford rtPA.

The mean age of our patients was 66 years, ranging from 32 to 82. Out of the 54 patients who were thrombolysed, 31 were males. Co-morbid illnesses in the form of hypertension, diabetes and hypercholesterolemia were present in 44 (64.7%), 22 (41.2%) and eight (14.7%) patients respectively. Additionally, atrial fibrillation was present in 11(20.6%), congestive heart failure in eight (14.7%) and coronary artery disease in six (11.8%). There was a history of prior stroke in 10 (17.7%). The mean blood pressure at admission was 156/88 mmHg and the mean maximum pretreatment blood pressure was 166/90 mmHg. Eighteen of the 54 (32.4%) patients were smokers [Table - 3].

The mean baseline NIHSS was 14 ± 2 (range 8-22). Using TOAST criteria, patients were classified into: large artery atherosclerotic = 13; cardioembolic = 12; small vessel occlusion = 22; other determined etiology = three; undetermined etiology = four. The mean time to reach emergency was 2.4h (1.15-3.4h). The mean door to CT time was 24 min (10-47 min). The mean door to rtPA injection time was 26.8 min (25-67 min). The NIHSS scores ranged from 11 to 22 min (mean = 15.5 ± 2.7). Patients with history of liver or renal disease or those on anticoagulants were excluded. The PT, aPTT and platelet count results were not obtained prior to thrombolysis. Early signs of infarction on CT were seen in 25/54 (46.3%) patients. These were sulcal effacement in 11, insular ribbon sign in six and loss of gray white matter definition in eight. Am infarct in the follow-up CT or MRI was present in 53 of our 54 patients (97.1%).

Mean length of hospitalization in our patients was nine days. During hospital stay, antihypertensive therapy had to be given to 44 (82.4%) patients. Antiplatelet drugs were given to all 54 patients while 10 (17.7%) received anticoagulants. No patient was given blood transfusion. Hemorrhagic conversion was noted in five (8.8%). Symptomatic intracranial hemorrhage or fatal hemorrhage did not occur in any of our patients.

Thirty-five patients (65%) significantly improved on NIHSS at 48h (³ 4 points) (mean change = 10; range = 4-17). At one month, 43 (79%) improved on Barthel Index (mean change = 45%). Of these, 19 (44% of the 43 patients improved; 35% of total number (54)), achieved ³ 95% scores on Barthel Index indicating near normal functional status. Of the stroke subtypes, cardioembolic and small vessel occlusions did better than others. Of the eight patients who showed no improvement, six were lacunar strokes. One developed small frontal lobe hemorrhage and recurrent stroke; one died of aspiration and eight showed no improvement. The mean length of follow-up after discharge was 9.5 ± 3 months. Although not part of the study protocol, modified Rankin Score (mRS) was administered at the end of three months to 48 (88%) patients (the rest could not be directly observed). The average mRS was 1.4 (0-2). One patient developed deep venous thrombosis of the saphenous vein and had to be hospitalized for treatment. One patient developed pneumonia and recovered with therapy.


 » Discussion Top


Despite the demonstration of benefit from thrombolytic treatment with intravenous rtPA by the NINDS trial as early as in 1995, this form of therapy has been relatively underused in developing countries. The reluctance to aggressively thrombolyse patients of acute ischemic stroke has been attributed to several factors including delay in the arrival of the patients to stroke units, limited resources, ignorance or disbelief amongst neurologists as to the efficacy of this form of treatment and a fear of serious rtPA-related complications.

We succeeded in treating 54 patients of acute ischemic stroke with IV rtPA over a period of four years. Importantly, we were unable to thrombolyse 38% of otherwise eligible patients due to delay in evaluation and treatment. Several studies have tried to analyze the causes of such delays but they have all been conducted in developed countries under very different circumstances.[7],[8],[9],[10],[11],[12]

The mean age of patients in our study was 66 years, whereas the mean age of patients in the NINDS trial was 67 years. Advanced age increases the odds of a poor outcome after thrombolysis.[13],[14] However, post hoc analysis of the NINDS data showed rtPA to be beneficial for patients in all strata of age. As stroke increases with age, it becomes important to decide if older patients should be denied this potentially disability-avoiding therapy.

Our patients had a mean baseline NIHSS of 14 which is similar to that of patients in the NINDS rtPA trial. The stroke subtype by final diagnosis was most often, in 35.3% patients, small vessel disease. The NINDS trial and a few subsequent studies have shown that intravenous thrombolysis within the three-hour time window is similar between different stroke subtypes.[1] It has therefore been recommended that extensive diagnostic evaluation to determine stroke subtypes before thrombolysis is neither required nor justified.

Patients arrived in the emergency department at an average of 150 min after the symptom onset. A CT scan was performed within 22 min and intravenous rtPA was administered within an average of 27 min from the time of arrival to the emergency department respectively. A significant difference between our experience and the NINDS trial is that half of the patients randomized in the NINDS study were treated within 90 min of stroke onset. However, the response to treatment observed in the NINDS trial between patients treated under 90 min and between 90 and 180 min did not differ. This underlines the importance of not withholding treatment from patients even if they present beyond 90 min of symptom onset. We were able to treat patients within an average of 27 min from their time of arrival at the emergency department. This is contrary to the popular perception that it is generally not possible to treat patients within the time window of 180 min in busy and constrained hospitals of developing countries unless they arrive early. Recent NIH consensus guidelines recommend a "door-to-needle" time of 60 min or less for acute stroke patients.

An improvement of four points or more on the NIHSS at 48h was seen in 65% of our patients while a Barthel Index of 75 or more at one month was present in 79% patients. It is important to note here that the long-term benefit as observed from the Barthel Index is significantly more impressive than the immediate benefit as reflected from the 48h NIHSS. The reluctance of many neurologists to treat patients is based on this premise of insufficient immediate improvement in outcome. However, it is equally important not to lose sight of the delayed benefits, especially considering the tremendous impact that stroke morbidity has on the individual, caregivers and society as a whole.

This preliminary data from a tertiary care center from a developing country shows that hyperacute thrombolysis in acute ischemic stroke is both feasible and useful. It also emphasizes the importance of increasing awareness about stroke and its acute management. More significantly, till such time that patients start presenting more promptly for treatment, it needs to be understood that thrombolysis can still be provided in hospitals if a dedicated stroke team endeavors to reduce the "door-to-needle" time to the minimum possible.

The limitation of the present study is the lack of a control group which will impede with the assessment of the efficacy of thrombolysis. However, since the study is strictly observational, it may be taken as a pilot project to evaluate essentially the feasibility and safety. The other limitation is the sample size. We accede that this is a small number to draw any definite conclusions. However, the observation does reveal that in this small number of patients, hyperacute thrombolysis can be undertaken in spite of not obtaining coagulation results in carefully screened patients of AIS. A future trial needs to be undertaken with a blinded, controlled and randomized design to substantiate the above findings.

 
 » References Top

1.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.   Back to cited text no. 2    
3.Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue - type plasminogen activator for acute ischemic stroke: A Cleveland update. Stroke 2003;34:799-800.   Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Kaste M. Thrombolysis in ischemic stroke - present and future: Role of combined therapy. Cerebrovasc Dis 2001;11:55-9.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Practice advisory: Thrombolytic therapy for acute ischemic stroke - summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835-9.  Back to cited text no. 5    
6.Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al . Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167-74.  Back to cited text no. 6    
7.Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederksen SM. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: A retrospective analysis. Acad Emerg Med 1999;6:618-25.   Back to cited text no. 7    
8.Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002;162:1994-2001.   Back to cited text no. 8  [PUBMED]  [FULLTEXT]
9.Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, et al . Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey. The t - PA Stroke Survey Group. Neurology 1999;53:424-7.   Back to cited text no. 9    
10.Clark WM, Lutsep HL. Medical treatment strategies: Intra-venous thrombolysis, neuronal protection and anti-reperfusion injury agents. Neuroimaging Clin N Am 1999;9:465-73.  Back to cited text no. 10  [PUBMED]  
11.Akins PT, Delemos C, Wentworth D, Byer J, Schorer SJ, Atkinson RP. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 2000;55:1801-5.   Back to cited text no. 11  [PUBMED]  [FULLTEXT]
12.Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000;31:77-81.   Back to cited text no. 12    
13.Koenneeke HC, Nohr R, Leister S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety and efficacy in a single - center, 2 - year experience. Stroke 2001;32:1074-8.   Back to cited text no. 13    
14.Schmulling S, Grand M, Rudolf J, Heis WD. One - year follow - up in acute stroke patients treated with rt - PA in clinical routine. Stroke 2000;31:1552-4.  Back to cited text no. 14    


    Tables

[Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 Risk Factors for Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Cerebral Infarction: A Retrospective Single-Center Study
Xiahong Xu,Changsong Li,Ting Wan,Xiaobo Gu,Wenxia Zhu,Junjie Hao,Huan Bao,Lian Zuo,Hui Hu,Gang Li
World Neurosurgery. 2017; 101: 155
[Pubmed] | [DOI]
2 Strategies to Improve Stroke Care Services in Low- and Middle-Income Countries: A Systematic Review
Jeyaraj Durai Pandian,Akanksha G. William,Mahesh P. Kate,Bo Norrving,George A. Mensah,Stephen Davis,Gregory A. Roth,Amanda G. Thrift,Andre P. Kengne,Brett M. Kissela,Chuanhua Yu,Daniel Kim,David Rojas-Rueda,David L. Tirschwell,Foad Abd-Allah,Fortuné Gankpé,Gabrielle deVeber,Graeme J. Hankey,Jost B. Jonas,Kevin N. Sheth,Klara Dokova,Man Mohan Mehndiratta,Johanna M. Geleijnse,Maurice Giroud,Yannick Bejot,Ralph Sacco,Ramesh Sahathevan,Randah R. Hamadeh,Richard Gillum,Ronny Westerman,Rufus Olusola Akinyemi,Suzanne Barker-Collo,Thomas Truelsen,Valeria Caso,Vasanthan Rajagopalan,Narayanaswamy Venketasubramanian,Vasiliy V. Vlassovi,Valery L. Feigin
Neuroepidemiology. 2017; 49(1-2): 45
[Pubmed] | [DOI]
3 Temporal Trends in Intravenous Thrombolysis in Acute Ischemic Stroke: Experience from a Tertiary Care Center in India
Dheeraj Khurana,Biplab Das,Ashok Kumar,Amith Kumar S.,Niranjan Khandelwal,Vivek Lal,Sudesh Prabhakar
Journal of Stroke and Cerebrovascular Diseases. 2017; 26(6): 1266
[Pubmed] | [DOI]
4 Interventions for acute stroke management in Africa: a systematic review of the evidence
Leonard Baatiema,Carina K. Y. Chan,Adem Sav,Shawn Somerset
Systematic Reviews. 2017; 6(1)
[Pubmed] | [DOI]
5 Gaps and Hurdles Deter against Following Stroke Guidelines for Thrombolytic Therapy in Iran: Exploring the Problem
Karim Nikkhah,Abolfazl Avan,Ali Shoeibi,Amir Azarpazhooh,Kavian Ghandehari,Christian Foerch,Gustavo Saposnik,Payam Sasannejad,Veda Vakili,Parvaneh Layegh,Mohammad Taghi Farzadfard,Reza Bavarsad Shahripour,Mohammad Reza Hosseini,Mahmoud Reza Azarpazhooh
Journal of Stroke and Cerebrovascular Diseases. 2015; 24(2): 408
[Pubmed] | [DOI]
6 Cost of stroke in low and middle income countries: a systematic review
Paramdeep Kaur,Gagandeep Kwatra,Raminder Kaur,Jeyaraj D. Pandian
International Journal of Stroke. 2014; 9(6): 678
[Pubmed] | [DOI]
7 Eligibility Assessment for Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients; Evaluating Barriers for Implementation
Hormoz Ayromlou,Hassan Soleimanpour,Mehdi Farhoudi,Aliakbar Taheraghdam,Elyar Sadeghi Hokmabadi,Rouzbeh Rajaei Ghafouri,Mehdi Najafi Nashali,Ehsan Sharifipour,Somayeh Mostafaei,Davar Altafi
Iranian Red Crescent Medical Journal. 2014; 16(5)
[Pubmed] | [DOI]
8 Postthrombolysis outcomes in acute ischemic stroke patients of Asian race-ethnicity
Nishant K. Mishra,Bernard P. L. Chan,Hock-Luen Teoh,Chang-Hui Meng,Kennedy R. Lees,Christopher Chen,Vijay K. Sharma
International Journal of Stroke. 2013; 8: 95
[Pubmed] | [DOI]
9 Thrombolysis for acute ischemic stroke in South Africa
Alan Bryer,Sean Wasserman
International Journal of Stroke. 2013; 8: 112
[Pubmed] | [DOI]
10 Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator
Vijay K Sharma,Ghulam Kawnayn,Nabin Sarkar
Expert Review of Neurotherapeutics. 2013; 13(8): 895
[Pubmed] | [DOI]
11 Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre
Wasserman, S. and Bryer, A.
South African Medical Journal. 2012; 102(6): 541-544
[Pubmed]
12 Is stroke thrombolysis safe and efficacious in Hong Kong? [Chinese Source]
Wong, E.H.C. and Lau, A.Y.L. and Soo, Y.O.Y. and Siu, D.Y.W. and Hui, V.S.W. and Graham, C.A. and Leung, T.W.H. and Wong, L.K.S.
Hong Kong Medical Journal. 2012; 18(2): 92-98
[Pubmed]
13 Intravenous thrombolysis for acute ischemic stroke in Asia
Vijay K Sharma, Kay WP Ng, Narayanaswamy Venketasubramanian, Hock L Teoh, Bernard PL Chan
Expert Review of Neurotherapeutics. 2012; 12(2): 209
[VIEW] | [DOI]
14 Barriers of thrombolysis therapy in developing countries
Ghandehari, K.
Stroke Research and Treatment. 2011; (686797)
[Pubmed]
15 Hospital-based management of acute ischemic stroke following intravenous thrombolysis
Raid G Ossi, James F Meschia, Kevin M Barrett
Expert Review of Cardiovascular Therapy. 2011; 9(4): 463
[VIEW] | [DOI]
16 Comment on "efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke"
Ahmad, A., Sharma, V.K.
Journal of Clinical Neuroscience. 2011; 18(1): 160-161
[Pubmed]
17 Current status of intravenous thrombolysis for acute ischemic stroke in Asia
Sharma, V.K. and Ng, K.W.P. and Venketasubramanian, N. and Saqqur, M. and Teoh, H.L. and Kaul, S. and Srivastava, P.M.V. and Sergentanis, T. and Suwanwela, N. and Nguyen, T.H. and Lawrence Wong, K.S. and Chan, B.P.L.
International Journal of Stroke. 2011; 6(6): 523-530
[Pubmed]
18 Risk factors and prognosis for hemorrhagic transformation caused by intravenous thrombolysis treatment with recombinant tissue plasminogen activator treatment in acute cerebral infarction
Su, M. and Yang, W.-X. and Wang, W.-H. and Cao, Y.-J. and Lu, T.-S. and Jiang, X.-F. and Kong, Y. and Liu, C.-F.
Chinese Journal of Neurology. 2011; 44(11): 754-758
[Pubmed]
19 Changing scenario of neuropractice
Yeolekar, M.E.
Journal of Neurosciences in Rural Practice. 2011; 2(1): 1-3
[Pubmed]
20 Comment on “Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke”
Aftab Ahmad,Vijay K. Sharma
Journal of Clinical Neuroscience. 2011; 18(1): 160
[Pubmed] | [DOI]
21 Current Status of Intravenous Thrombolysis for Acute Ischemic Stroke in Asia
Vijay K. Sharma,Kay W. P. Ng,Narayanaswamy Venketasubramanian,Maher Saqqur,Hock L. Teoh,Subash Kaul,Padma M. V. Srivastava,Theodoris Sergentanis,Nijasri Suwanwela,Thang H. Nguyen,K. S. Lawrence Wong,Bernard P. L. Chan
International Journal of Stroke. 2011; 6(6): 523
[Pubmed] | [DOI]
22 Barriers of Thrombolysis Therapy in Developing Countries
Kavian Ghandehari
Stroke Research and Treatment. 2011; 2011: 1
[Pubmed] | [DOI]
23 Feasibility and Safety of Intravenous Thrombolysis in Multiethnic Asian Stroke Patients in Singapore
Vijay K. Sharma,Georgios Tsivgoulis,June H. Tan,Lily Y.H. Wong,Benjamin K.C. Ong,Bernard P.L. Chan,Hock L. Teoh
Journal of Stroke and Cerebrovascular Diseases. 2010; 19(6): 424
[Pubmed] | [DOI]
24 Comment on “Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008”
Vijay K. Sharma,Hock L. Teoh,Bernard P.L. Chan
Journal of Clinical Neuroscience. 2010; 17(4): 543
[Pubmed] | [DOI]
25 Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry
T. H. Nguyen,A. L. T. Truong,M. B. Ngo,C. T. Q. Bui,Q. V. Dinh,T. C. Doan,L. T. K. Nguyen,T. C. Phan,M. V. Phan,T. V. Nguyen,T. V. Le
European Journal of Neurology. 2010; 17(9): 1188
[Pubmed] | [DOI]
26 Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan
Mohammad Wasay, Hazim Barohi, Abdul Malik, Adnan Yousuf, Safia Awan, Ayeesha K. Kamal
Neurological Sciences. 2010; 31(2): 223-225
[Pubmed] | [DOI]
27 Comment on "Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008"
Sharma, V.K., Teoh, H.L., Chan, B.P.L.
Journal of Clinical Neuroscience. 2010; 17(4): 543-544
[Pubmed]
28 Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in acute ischemic stroke
Loh, P.K., Sharma, V.K.
Stroke. 2010; 41(3): e164
[Pubmed]
29 Patients with thrombolysed stroke in Vietnam have an excellent outcome: Results from the Vietnam Thrombolysis Registry
Nguyen, T.H. and Truong, A.L.T. and Ngo, M.B. and Bui, C.T.Q. and Dinh, Q.V. and Doan, T.C. and Nguyen, L.T.K. and Phan, T.C. and Phan, M.V. and Nguyen, T.V. and Le, T.V.
European Journal of Neurology. 2010; 17(9): 1188-1192
[Pubmed]
30 Low-dose versus standard-dose tissue plasminogen activator for intravenous thrombolysis in asian acute ischemic stroke patients
Ng, K.W.P., Sharma, V.K.
Stroke. 2010; 41(8): e545-e546
[Pubmed]
31 Feasibility and safety of intravenous thrombolysis in multiethnic asian stroke patients in singapore
Sharma, V.K., Tsivgoulis, G., Tan, J.H., Wong, L.Y.H., Ong, B.K.C., Chan, B.P.L., Teoh, H.L.
Journal of Stroke and Cerebrovascular Diseases. 2010; 19(6): 424-430
[Pubmed]
32 Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008
K.A. Salam,K. Ummer,V.G. Pradeep Kumar,M.L. Noone,A. Laila,J. Ragini
Journal of Clinical Neuroscience. 2009; 16(10): 1276
[Pubmed] | [DOI]
33 Safety and efficacy of IV-TPA for ischaemic stroke in Clinical practice - A bayesian analysis
OæRourke, K.E.T., Walsh, C.D., Kelly, P.J.
Cerebrovascular Diseases. 2009; 28(6): 572-581
[Pubmed]
34 Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008
Salam, K.A., Ummer, K., Pradeep Kumar, V.G., Noone, M.L., Laila, A., Ragini, J.
Journal of Clinical Neuroscience. 2009; 16(10): 1276-1278
[Pubmed]
35 Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA
Ghandehari, K., Pour Zahed, A., Taheri, M., Abbasi, M., Gorjestani, S., Moghaddam Ahmadi, A., Nahayati, M.A.
International Journal of Stroke. 2009; 4(4): 236
[Pubmed]
36 Estimation of Iranian Stroke Patients Eligible for Intravenous Thrombolysis with tPA
K. Ghandehari,A. Pour Zahed,M. Taheri,M. Abbasi,S. Gorjestani,A. Moghaddam Ahmadi,M. A. Nahayati
International Journal of Stroke. 2009; 4(4): 236
[Pubmed] | [DOI]
37 Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
Sharma, S., Sharma, N.
Annals of Indian Academy of Neurology. 2008; 11(4): 221-224
[Pubmed]
38 Hyperacute stroke imaging: How much is enough?
Sanghvi, D., Anand, S., Limaye, U.
Indian Journal of Radiology and Imaging. 2007; 17(4): 237-241
[Pubmed]
39 Poverty and stroke in India: A time to act
Pandian, J.D., Srikanth, V., Read, S.J., Thrift, A.G.
Stroke. 2007; 38(11): 3063-3069
[Pubmed]
40 Thrombolysis with tissue plasminogen activator: Protocol violation is not an option [3]
Kumar, S.
Neurology India. 2007; 55(2): 174
[Pubmed]
41 Stroke and thrombolysis in India [1]
Pandian, J.
Neurology India. 2007; 55(2): 173
[Pubmed]
42 Thrombolytic treatment in acute cerebral infarction
Arboix, A.
Neurology India. 2007; 55(1): 8-9
[Pubmed]
43 Thrombolysis for acute ischemic stroke in India: Overcoming the challenges
Hussain, M., Shuaib, A.
Neurology India. 2007; 55(1): 9-10
[Pubmed]
44 Thrombolysis for stroke in India: Miles to go...
Murthy, J.M.K.
Neurology India. 2007; 55(1): 3-5
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow